Financials
Financial year 2025
FEBELFARMA from Sint-Niklaas, company number BE0479127936, closed financial year 2025 with a result of € 45,753 after tax. For that financial year FEBELFARMA recorded revenue of € 59,365 and equity of € 2 million. Compared with financial year 2024, the result moved from € 608,557 to € 45,753. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.
€ 2 million
▲ 2% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 45,753
▼ 92% vs 2024
Profit after tax over the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 1.5 million.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 11,229
▲ € 8,562 vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 100 days on average.
€ 17,953
▲ € 14,772 vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 15,531 | € 29,774 | € 40,015 | € 59,365 | ▲ 48% |
| Profit after taxes | € 40,155 | € 24,259 | € 608,557 | € 45,753 | ▼ 92% |
| Equity | € 1,349,142 | € 1,373,401 | € 1,981,958 | € 2,027,711 | ▲ 2% |
| Total debts | € 9,325 | € 11,259 | € 14,518 | € 29,699 | ▲ 105% |
| Retained profit | € 798,566 | € 822,825 | € 1,431,382 | € 1,477,135 | ▲ 3% |
| Balance sheet total | € 1,358,466 | € 1,384,660 | € 1,996,476 | € 2,057,410 | ▲ 3% |
Key figures of FEBELFARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to FEBELFARMA?
What happened at FEBELFARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 45,753 (▼ 92% vs 2024). filed late Source: NBB ↗
- New establishment in Sint-Niklaas. KBO
- Start of the company according to the CBE. KBO
In short
From € 40,155 profit in 2022 to € 45,753 profit in 2025.
Paid € 35,387 in corporate taxes since 2022.
Best year ever: 2024, with € 608,557 profit.
Pays suppliers within 100 days on average.
A new publication or filing at FEBELFARMA? We notify you, reason included.
Follow FEBELFARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of FEBELCO comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
FEBELFARMABehind FEBELFARMA are Alexo BV, Aristo BV and Eric Van Nueten. The shares are held by FEBELCO (99.8%). It owns 25% of Pharmacie Coloniale, 0.1% of Axone Pharma and 0% of Livlina itself.
Directors
According to the 2025 annual accounts
Managing director · represented by Olivier Delaere
Also active at: SDC, HC Pharma, SODIAP, APOTHEEK JENNE, PANNOC CHEMIE, Apotheek de Lisseweg, Apotheek Seurinck, APOTHEEK SCARPHOUT +34 more
Chairman of the board · represented by Frank Coene
Also active at: LIVLINA, FEBELCO, FEBELCOFONDS, AXONE PHARMA, LIVLINA TRANSPORT
Eric Van Nueten
Director
Also active at: APOTHEEK MOLENVELD, FEBELCO, FEBELCOFONDS, EVN CONSULTING, E.V.N. PHARMA
Shareholders
99.8%
Participations
Establishments
Establishment units
Physical locations of this company
Eigenlostraat 1
9100 Sint-Niklaas
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0479.127.936
- VAT number
- BE 0479.127.936
- Registered office
- Eigenlostraat 1, 9100 Sint-Niklaas
- Names & denominations
- FEBELFARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 23 December 2002
- Peppol
- Active · Active since 23 Dec 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsvoering en beheer
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Overige vormen van onderwijs